Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.

Authors:
Wang Y; Li P; Lavrijsen M; Li Y; Ma Z and 3 more

Journal:
Arch Virol

Publication Year: 2022

DOI:
10.1007/s00705-022-05369-y

PMCID:
PMC8853085

PMID:
35171357

Journal Information

Full Title: Arch Virol

Abbreviation: Arch Virol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestAll authors declare no competing interests. Conflict of interest All authors declare no competing interests."

Evidence found in paper:

"This study was supported by a VIDI Grant (no. 91719300) from the Netherlands Organization for Scientific Research (NWO) to Q. Pan a grant from and the China Scholarship Council for funding Ph.D. fellowships to Yining Wang (no. 201903250082) and Pengfei Li (no. 201808370170). The authors thank Dr. Lia van der Hoek (Amsterdam UMC location AMC, University of Amsterdam, The Netherlands) for providing the stock of human coronavirus NL63. The authors also thank Dr. Bart Haagmans (Department of Viroscience, Erasmus MC) for providing the stock of SARS-CoV-2 and SARS-CoV-2 B.1.617.2 Delta variant."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025